Mieloma multiplo: arriva l'approvazione europea per isatuximab come prima linea in pazienti non candidabili al trapianto.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback